Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth A Raetz

Showing results (111-120 of 155) with videos related to

Pageof 16
Sort By:
The Lancet. Haematology|July 5, 2023
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trialStephen P Hunger, Thai Hoa Tran, Vaskar Saha, et al.
Nature Communications|July 8, 2025
Inferring chromosome segregation error stage and crossover in trisomic disorders with application to Down syndromeZhenhua Li, Wenjian Yang, Gang Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2019
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331Kelly W Maloney, Meenakshi Devidas, Cindy Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2021
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932Anne L Angiolillo, Reuven J Schore, John A Kairalla, et al.
Leukemia|March 25, 2023
Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932Reuven J Schore, Anne L Angiolillo, John A Kairalla, et al.
Leukemia|May 8, 2023
Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932Reuven J Schore, Anne L Angiolillo, John A Kairalla, et al.
Leukemia|February 24, 2018
Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG)Sumit Gupta, Meenakshi Devidas, Mignon L Loh, et al.
Cancer|October 30, 2019
Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task ForceEtan Orgel, Thomas B Alexander, Brent L Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2021
Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331Leonard A Mattano, Meenakshi Devidas, Kelly W Maloney, et al.
Haematologica|June 13, 2024
Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed <i>KMT2A</i>-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1Erin M Guest, John A Kairalla, Meenakshi Devidas, et al.
Pageof 16

Showing results (111-120 of 155) with videos related to

Sort By:
Pageof 16
The Lancet. Haematology|July 5, 2023
Dasatinib with intensive chemotherapy in de novo paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (CA180-372/COG AALL1122): a single-arm, multicentre, phase 2 trialStephen P Hunger, Thai Hoa Tran, Vaskar Saha, et al.
Nature Communications|July 8, 2025
Inferring chromosome segregation error stage and crossover in trisomic disorders with application to Down syndromeZhenhua Li, Wenjian Yang, Gang Wu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2019
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0331Kelly W Maloney, Meenakshi Devidas, Cindy Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2021
Excellent Outcomes With Reduced Frequency of Vincristine and Dexamethasone Pulses in Standard-Risk B-Lymphoblastic Leukemia: Results From Children's Oncology Group AALL0932Anne L Angiolillo, Reuven J Schore, John A Kairalla, et al.
Leukemia|March 25, 2023
Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932Reuven J Schore, Anne L Angiolillo, John A Kairalla, et al.
Leukemia|May 8, 2023
Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932Reuven J Schore, Anne L Angiolillo, John A Kairalla, et al.
Leukemia|February 24, 2018
Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG)Sumit Gupta, Meenakshi Devidas, Mignon L Loh, et al.
Cancer|October 30, 2019
Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task ForceEtan Orgel, Thomas B Alexander, Brent L Wood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 19, 2021
Favorable Trisomies and <i>ETV6-RUNX1</i> Predict Cure in Low-Risk B-Cell Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Trial AALL0331Leonard A Mattano, Meenakshi Devidas, Kelly W Maloney, et al.
Haematologica|June 13, 2024
Azacitidine as epigenetic priming for chemotherapy is safe and well-tolerated in infants with newly diagnosed <i>KMT2A</i>-rearranged acute lymphoblastic leukemia: Children's Oncology Group trial AALL15P1Erin M Guest, John A Kairalla, Meenakshi Devidas, et al.
Pageof 16